Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

SAB Biotherapeutics (SABS) Interest Coverage Ratio (2021 - 2025)

Historic Interest Coverage Ratio for SAB Biotherapeutics (SABS) over the last 5 years, with Q3 2025 value amounting to 292.87.

  • SAB Biotherapeutics' Interest Coverage Ratio fell 10208.45% to 292.87 in Q3 2025 from the same period last year, while for Sep 2025 it was 174.11, marking a year-over-year decrease of 942.46%. This contributed to the annual value of 134.77 for FY2024, which is 1159.58% down from last year.
  • According to the latest figures from Q3 2025, SAB Biotherapeutics' Interest Coverage Ratio is 292.87, which was down 10208.45% from 151.25 recorded in Q2 2025.
  • Over the past 5 years, SAB Biotherapeutics' Interest Coverage Ratio peaked at 10.82 during Q1 2021, and registered a low of 292.87 during Q3 2025.
  • For the 5-year period, SAB Biotherapeutics' Interest Coverage Ratio averaged around 115.96, with its median value being 109.56 (2024).
  • Per our database at Business Quant, SAB Biotherapeutics' Interest Coverage Ratio plummeted by 96034.54% in 2022 and then skyrocketed by 4172.98% in 2024.
  • Quarter analysis of 5 years shows SAB Biotherapeutics' Interest Coverage Ratio stood at 110.81 in 2021, then rose by 19.12% to 89.62 in 2022, then plummeted by 170.4% to 242.35 in 2023, then skyrocketed by 41.73% to 141.22 in 2024, then crashed by 107.39% to 292.87 in 2025.
  • Its Interest Coverage Ratio was 292.87 in Q3 2025, compared to 151.25 in Q2 2025 and 154.85 in Q1 2025.